Two case histories of severe, early onset intrauterine growth retardation are presented. Intravenous prostacyclin was administered in an attempt to promote fetal growth and thus prolong the pregnancy, but was unsuccessful and resulted in intrauterine death in each case. The possible reasons for the failure of this treatment and alternative therapeutic options are discussed.
Introduction
Repeated spontaneous abortion, intrauterine growth retardation (IUGR), intrauterine death (IUD) and preeclampsia(PE)can be regarded as conditions associated with a defective maternal response to pregnancy, and as such have many common features. The basis for these various manifestations of pregnancy failure, in the absence of specific maternal vascular disease such as systemic lupus erythematosus, may be an immunological failure of the process which enables the mother to recognize foreign trophoblastic tissue. This results in limited trophoblastic invasion of the spiral arteries. Evidence for this has been demonstrated from studies on placental bed biopsies 1 ,2, which show that spiral arteries with limited trophoblastic invasion are relatively vasoconstricted and probably remain responsive to pressor agents.
Role of prostaglandins
During normal pregnancy, in vitro studies have shown that human myometrium, decidua, placenta and placental membranes are capable of synthesizing the vasodilatory and anti-platelet aggregatory prostacyclin (PGI 2 )3. This production increases with gestation, as evidenced by increased maternal urinary excretion of PGI 2 metabolites", Both maternal platelets and fetoplacental tissues also produce increased amounts of the vasoconstrictor and pro-aggregatory prostaglandin, thromboxane (TXA 2 ) during pregnancy. Quantitatively, PGI 2 production is 5-10 times greater than that of TXA 2 • In pre-eclampsia, a deficiency of PGI 2 in placental and umbilical vessels has been demonstrated", This may also be associated with repeated abortion, IUGR and/or IUDs.7. Maternal urinary PGI 2 metabolites are depressed in pre-eclampsia". The platelet TXA 2 pathway, however, is enhanced in both normotensive and hypertensive pregnancies associated with IUGRs. This PGI 2f1'XA2 imbalance may account for the platelet aggregation and vasoconstriction seen in preeclampsia and IUGR, and may further compromise the uteroplacental circulation.
Attempts to redress this prostaglandin imbalance have led to the therapeutic application of PGI 2 administration in both PE and IUGR (Calder A, personal communication).
Use of prostacyclin
There are many difficulties involved with prostacyclin administration. Since its half-life is only 2-3 minutes it must be administered by chronic continuous intravenous infusion via a central line. It has notable side effects, including intestinal colic, nausea, facial flushing, headache and hypotension'', There have also been case reports of the occurrence of depression following intravenous PGI 2 infusionw.
We report here the cases of2 women who presented with previous pregnancy losses and severe, early IUGR, in whom intravenous PGI 2 was unsuccessful in prolonging their pregnancies to fetal viability.
Case reports
In both pregnancies gestational age was confirmed by ultrasound in early pregnancy, but subsequent ultrasound examination demonstrated symmetrical intrauterine growth retardation11 at 20 and 24 weeks respectively. Maternal investigations revealed normal coagulation studies, and no evidence of autoantibodies or of the lupus anticoagulant. After admission to hospital, a continuous infusion of PGI 2 was commenced and increased until maternal side effects were obtained. The dose was then reduced by one increment. In each case this gave a rate of 4 ng/kg/min. Patients were monitored with daily platelet counts, weekly ultrasound examination for growth and three times weekly continuous wave Doppler blood flow studies of both the maternal and fetal circulation.
Case 1: A 20-year-old Asian housewife had suffered a previous intrauterine death of a male fetus at 20 weeks' gestation; no obvious cause was found. In her second pregnancy, ultrasound examination at 19 weeks showed symmetrical IUGR, with severe oligohydramnios and absent fetal movement over 30 minutes. Continuous wave Doppler blood flow studies demonstrated a high resistance pattern from the uteroplacental arteries and the umbilical artery12 ( Figure 1 ). She was admitted to hospital and a continuous intravenous infusion of prostacyclin was commenced via a central line and syringe pump. During the 39 days of the infusion there was no apparent change in the resistance index of the uteroplacental arteries or umbilical artery, but fetal growth was demonstrated on ultrasound scans ( Figure 2 ). However, 11 days later loss of end-diastolic flow in the umbilical artery flow-velocity waveform ( Figure 3) was observed, suggesting a severely compromised fetus".
Thirty-nine days after the infusion was started and at 24 weeks' gestation fetal death occurred. The PGI 2 infusion was discontinued and the patient became hypertensive (170/110 mmHg) with heavy proteinuria on Labstix testing. A female fetus weighing only 170 g was aborted after extraamniotic prostaglandin E 2 (PGE z) infusion, following which the patient's blood pressure settled and the proteinuria resolved. Histology revealed a structurally normal fetus.
Case 2: A 25-year-old Caucasian housewife presented at 24 weeks' gestation for Doppler blood flow studies in view of her poor past obstetric history. Her first pregnancy resulted in a stillborn female infant weighing 1900 g at 39 weeks.
The following year she had a spontaneous abortion at 16 weeks, followed by a second stillbirth, delivering a male fetus of 2000 gat 36 weeks. However, the following year she delivered a healthy female infant weighing 2800 g at 37 weeks. The first and the third pregnancies were also associated with hypertension. After her only successful pregnancy, she had a puerperal pulmonary embolism. At 24 weeks' gestation the fetus demonstrated symmetrical IUGR, and Doppler blood flow studies showed a high resistance pattern in the uteroplacental arteries with absence of end-diastolic flow in the umbilical artery flow velocity waveform. An ultrasound-directed fetal blood sample from the umbilical cord was performed, which demonstrated a normal female karyotype and negative viral antibody screen. Low-dose subcutaneous heparin was given in view of her previous pulmonary embolus. A prostacyclin infusion was commenced via a central line, and after two weeks apparent fetal growth was demonstrated, but there was no obvious improvement in Doppler assessment of the uteroplacental or the fetal circulations.
After 19 days' treatment and at 17 weeks' gestation the infusion was discontinued following a marked fall in platelet count from. 290 to 38x 10 9/1. The following day, Doppler studies of umbilical artery blood flow demonstrated the extreme finding of reversal of flow during diastole ( Figure 4 ) and 24 hours later fetal death occurred. A female fetus weighing 540 g was aborted after extra-amniotic PGE z. Histology revealed no abnormalities of the fetus, but placental examination demonstrated maternal floor infarction, which has been described" in association with recurrent pregnancy loss.
Discussion
These treatment failures may have occurred for several reasons. First, the infusion rate of4 ng/kg/min, which was limited by maternal side effects, may have represented an ineffective dose. Other workers" also found this to be the maximum infusion rate tolerated by the patient when they treated a hypertensive woman at 25 weeks' gestation after demonstrating a significant fall in maternal plasma concentration of a breakdown product of PGI 2 , 6-oxo PGF 1 • They attributed their lack of success in prolonging the pregnancy to the fact that treatment was commenced too late.
The second wave of trophoblastic invasion into the myometrial segments of the spiral arteries can begin as early as 16 weeks,and be completeby 24 weeks.The obvious problem is that by the time a reduction in fetal growth rate has been demonstrated with ultrasound, the stage has already been set in the spiral arteries for 'placental insufficiency', and any treatment may be too late to prevent this derangement in the blood supply to the placenta from affecting the fetus.
Deficient trophoblastic invasion may be associated with a local under-production of PGI 2 which could begin as early as 16-18 weeks. This would lead to chronic vasospasm, platelet aggregation and thrombosis of the uninvaded spiral arteries. PGI 2 administration may therefore be necessary from 16 weeks if it is to influence this process.
Another possibility is that replacement of PGI 2 by exogenous administration is less effective in restoring the PGI 2fI'XA2 ratio attempts than to influence the endogenous production of these two prostaglandins.
Alternative therapeutic options which involve manipulation of the prostaglandin synthetic pathway have also been explored. Elder & Myatt" reported a successful pregnancy outcome after the use of the antithrombotic drug, N afazatrom, which stimulates PGI 2 syntheais!". Treatment was begun at 6 weeks' gestation. Phosphodiesterase inhibition by dipyridamole, in association with cyclo-oxygenase inhibition by aspirin, has also been deseribedt'' in the prevention of pre-eclampsia. The recent use of low-dose aspirin'? in the prevention of pre-eclampsia is perhaps the most encouraging of recent reports. Low-dose aspirin differentially inhibits platelet cyclo-oxygenase resulting in reduced TXAl o and increased PGI 2 synthesis, thus restoring the PGI 2fI'XA2 ratio to normal. There was no reported abnormal fetal or maternal bleeding with a daily dose of 60 mg aspirin. A synergistic effect has been observed in vitro between aspirin and a calcium channel blocking agent (Nicardipinef", which may prove to be of clinical value.
Ifit is accepted that pharmacological treatment may need to be commenced before clinical evidence of a failing pregnancy, claims of drug-associated successes must be interpreted with caution, since there is no way of knowing what the outcome would have been without treatment. Treatment may be given on the basis of the past obstetric history. There is a relative risk of 3.4 of the occurrence of IUGR among second singleton births when the first infant's birth weight was less than the 10th percentile's, This risk may be even greater when applied to severe IUGR of early onset, as in the cases described here.
A sensitive screening test is required which can be performed early in pregnancy to detect those pregnancies which may be complicated by IUGR. Doppler ultrasound studies of the uteroplacental circulation provide an assessment of resistance to blood flow, and normal resistance correlates with the presence of physiological trophoblastic invasionl''. This test has been described as a screening test for PE and/or IUGR23 (Steel & Pearce 1987, in preparation) .
However, the second wave of trophoblastic invasion may not occur in some normal pregnancies until 24 weeks' gestation, as evidenced by the fact that Doppler studies may initially show a high resistance pattern, only to become normal by 24 weeks. Therefore, if conclusions regarding the risk of IUGR cannot be made until 24 weeks on the basis of this test, it may again be too late to consider pharmacological intervention. However, with increased understanding of the significance of early uteroplacental resistance patterns, the sensitivity of this screening test may improve.
In conclusion, severe early onset IUGR remains difficult to treat; the administration of exogenous prostacyclin poses practical problems and is of questionable value. If drug therapy is the answer, the results of the planned multicentre, randomized controlled trial of aspirin therapy should be awaited with interest.
